权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Therapeutics for Pox, Filo and Other Viral Pathogens

痘、丝状病毒和其他病毒病原体的治疗

基本信息

批准号：
7188078
负责人：
Stewart W. Schneller
金额：
$ 123万
依托单位：
AUBURN UNIVERSITY AT AUBURN
依托单位国家：
美国
项目类别：
财政年份：
2003
资助国家：
美国
起止时间：
2003-08-01 至 2009-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7188078
关键词：
Address Affect Age Alabama Antiviral Agents Belgium Biological Biological Products Bioterrorism Chemistry Collaborations Communicable Diseases Cowpox virus DNA-Directed RNA Polymerase Development Enzymes Filovirus Goals Guanosine Health Hydrolase Individual Infection Inosine Monophosphate Junin virus Medical Messenger RNA Metabolism Methyltransferase Mind National Institute of Allergy and Infectious Disease Nucleosides Nucleotides Numbers Orthopoxvirus Oxidoreductase Pharmaceutical Preparations Population Preparation Purpose Research Research Institute S-Adenosylmethionine Screening procedure Smallpox Smallpox Vaccine Tacaribe virus Therapeutic Therapeutic Agents Time USA Georgia Uncertain Risk Universities Utah Vaccination Vaccines Vaccinia Venezuelan Equine Encephalomyelitis Viral Viral Hemorrhagic Fevers Virus Virus Diseases Virus Replication West Nile virus Western Asia Georgia Yellow Fever base design inhibitor/antagonist mRNA capping nucleic acid metabolism nucleoside analog organizational structure pathogen

项目摘要

DESCRIPTION (provided by applicant): The possibility for biological terrorism has moved from the realm of speculation into reality. As a consequence, the National Institute of Allergy and Infectious Diseases has identified a number of agents that pose the greatest threat and has recommended that therapeutic agents be developed against them. Among that group of pathogens are smallpox and the viral hemorrhagic fevers (including the filoviruses Ebola and Marburg). In preparation for possible release of smallpox, plans are well underway to avail sufficient quantities of smallpox vaccine for a large number of people. However, within this population, there are individuals who will not be able to tolerate the vaccine or, for pre-existing health and/or age reasons, will not be suitable to receive vaccine protection. Thus, for these and other reasons, therapeutic agent development has been recommended by the NIAID. This proposal deals with two therapeutic goals in this direction: (i) agents for treating smallpox infection for instances where the vaccine was ineffective, not available or not administered for reasons just outlined, and (ii) drugs to counteract the effects of vaccination when administered. For the filoviruses Ebola and Marburg, which manifest themselves differently than smallpox but still produce horrendous effects, there are currently no pre-infection vaccines nor post-infection therapeutics available. To address these situations, plans are put forth for designing and developing drugs that would act by inhibiting viral replicative steps following infection by these viruses. Focus will be on nucleosides and nucleotides that affect, primarily, nucleic acid metabolism. A consortium of 3 chemists and 10 virologists has been assembled for this purpose. Because of the extensive collaborations that have been ongoing for some time by this group of chemists and virologists, it can be expected that promising anti-orthopoxvirus and anti-filovirus agents will be uncovered.

描述（申请人提供）：生物恐怖主义的可能性已经从猜测变成现实。因此，国家过敏和传染病研究所已经确定了一些构成最大威胁的制剂，并建议开发针对这些制剂的治疗剂。这类病原体包括天花和病毒性出血热（包括丝状病毒埃博拉和马尔堡）。为了准备可能的天花疫情，计划正在顺利进行，以便为大量人群提供足够数量的天花疫苗。然而，在这一人群中，有些人不能耐受疫苗，或者由于预先存在的健康和/或年龄原因，不适合接受疫苗保护。因此，由于这些和其他原因，NIAID建议开发治疗剂。该建议涉及这方面的两个治疗目标：（i）用于治疗天花感染的药剂，用于疫苗无效、不可用或由于刚才概述的原因而未施用的情况，以及（ii）在施用疫苗时抵消疫苗接种效果的药物。对于丝状病毒埃博拉病毒和马尔堡病毒，它们表现出与天花不同的症状，但仍然产生可怕的影响，目前没有感染前疫苗或感染后治疗方法。为了解决这些情况，提出了设计和开发药物的计划，这些药物将通过抑制这些病毒感染后的病毒复制步骤来起作用。重点将放在核苷和核苷酸的影响，主要是，核酸代谢。为此目的，已组建了一个由3名化学家和10名病毒学家组成的联合体。由于这组化学家和病毒学家已经进行了一段时间的广泛合作，可以预期将发现有希望的抗正痘病毒和抗丝状病毒药物。